Annals of Pediatric Gastroenterology and Hepatology ISPGHAN

Register      Login

VOLUME 3 , ISSUE 4 ( October-December, 2021 ) > List of Articles

Clinical Synopsis

Drug Update: Rifaximin

Citation Information : Drug Update: Rifaximin. Ann Pediatr Gastroenterol Hepatol 2021; 3 (4):5-6.

DOI: 10.5005/jp-journals-11009-0102

License: CC BY-NC 4.0

Published Online: 11-07-2022

Copyright Statement:  Copyright © 2021; The Author(s).


PDF Share
  1. Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol. 2010 Jan;26(1):17-25. doi: 10.1097/MOG.0b013e328333dc8d. PMID: 19881343; PMCID: PMC4737517.
  2. Javier A. Adachi, Herbert L. DuPont. Rifaximin: A Novel Nonabsorbed Rifamycin for Gastrointestinal Disorders. Clinical Infectious Diseases, Volume 42, Issue 4, 15 February 2006, Pages 541–547,
  3. Gathe JC Jr, Mayberry C, Clemmons J, et al. Resolution of severe cryptosporidial diarrhea with rifaximin in patients with AIDS. J Acquir Immune Defic Syndr. 2008; 48:363–364. [PubMed: 18580340]
  4. Avelar Rodriguez D, Ryan PM, Toro Monjaraz EM, Ramirez Mayans JA, Quigley EM. Small Intestinal Bacterial Overgrowth in Children: A State-Of-The-Art Review. Front Pediatr. 2019 Sep 4;7:363. doi: 10.3389/fped.2019.00363. PMID: 31552207; PMCID: PMC6737284.
  5. Devanarayana NM, Rajindrajith S. Irritable bowel syndrome in children: Current knowledge, challenges and opportunities. World J Gastroenterol 2018; 24(21): 2211-2235 [PMID: 29881232 DOI: 10.3748/wjg.v24.i21.2211]
  6. Bruzzese E, Pesce M, Sarnelli G, Guarino A. Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome. Expert Opin Drug Metab Toxicol. 2018 Jul;14(7):753-760. doi: 10.1080/17425255.2018.1488964. Epub 2018 Jun 22. PMID: 29897844.
  7. Muniyappa P, Gulati R, Mohr F, Hupertz V. Use and safety of rifaximin in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009 Oct;49(4):400-4. doi: 10.1097/MPG.0b013e3181a0d269. PMID: 19668011.
  8. Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005; 51 Suppl. 1: 36-66
  9. Ladevaia MD, Prete AD, Cesaro C, Gaeta L, Zulli C, Loguercio C. Rifaximin in the treatment of hepatic encephalopathy. Hepat Med. 2011 Dec 22;3:109-17. doi: 10.2147/HMER.S11988. PMID: 24367227; PMCID: PMC3846583.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.